Hutchison China MediTech’s (NASDAQ:HCM)
New Drug Application (“NDA”) for savolitinib for the treatment of
non-small cell lung cancer (“NSCLC”) with MET Exon 14 skipping mutations
has been accepted for review by the China National Medical Products
Administration.
An updated analysis with 70 patients will be
presented as part of the American Society of Clinical Oncology (“ASCO”)
2020 Meeting, available on May 29, 2020 at 8:00 a.m. ET.
In 2011, Chi-Med entered into a global licensing and joint development agreement with AstraZeneca (NYSE:AZN) for savolitinib.
https://seekingalpha.com/news/3578576-chi-meds-nda-for-savolitinib-accepted-in-china
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.